
Fluicell Investor Relations Material
Latest events

Q1 2025
9 May, 2025

Q4 2024
21 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Fluicell
Access all reports
Fluicell is a biotech company that specializes in pioneering solutions for bioprinting and single-cell biology. Established in 2012 as a spin-off from Chalmers University of Technology in Gothenburg, Sweden, Fluicell has developed a reputation for its innovative approach to studying and manipulating individual cells with precision. The company's flagship technology, Biopixlar, is a high-resolution 3D bioprinting platform capable of constructing biological tissues at the single-cell level without the need for bioink. This technology is utilized in the development of tissue-based therapies for serious diseases lacking adequate treatments, such as type 1 diabetes, cardiovascular disease, and kidney disease.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
FLUI
Country
🇸🇪 Sweden